Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Olink's Proseek Multiplex, Thermo's Nanospray Flex Ion Source

Premium

Olink has launched Proseek Multiplex, a set of multiplexed protein biomarker immunoassays based on its Proximity Extension Assay platform that enable researchers to quantify 92 proteins in a one-microliter sample.

The first entry in the product line is Proseek Multiplex Oncology I 96x96, which analyzes 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens.

The company plans to release additional Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes later this year.

Olink said that the minimal sample requirements of Proseek Multiplex make it particularly useful for biomarker discovery using biobanked serum samples, tissue lysates of needle biopsies, and microdialysis samples. The company said the Proseek assays provide accurate quantification below picogram-per-milliliter levels.

Proseek Multiplex is for research use only.


Thermo Fisher Scientific has released an UHPLC liquid junction kit for its Nanospray Flex Ion Source for electrospray ionization LC-MS.

The company said that the new kit elevates packed tip column performance to "UHPLC levels."

The Nanospray Flex source provides ion generation for nano-electrospray for all current Thermo Scientific mass spectrometers.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more